These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 10340924)

  • 1. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
    Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
    J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene.
    Raijmakers MT; Jansen PL; Steegers EA; Peters WH
    J Hepatol; 2000 Sep; 33(3):348-51. PubMed ID: 11019988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
    Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
    Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of rapid polymerase chain reaction-based detection of all length polymorphisms in the UGT 1A1 gene promoter.
    Huang CK; Dulau A; Su-Rick CJ; Pan Q
    Diagn Mol Pathol; 2007 Mar; 16(1):50-3. PubMed ID: 17471158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study of polymorphism in UDP-glucuronosyltransferase 1 (UGT-1A1) promoter gene in Korean patients with Gilbert's syndrome].
    Kim YH; Yeon JE; Jung GM; Kim HJ; Kim JS; Byun KS; Bak YT; Lee CH
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):132-8. PubMed ID: 12499798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter.
    Hsieh TY; Shiu TY; Huang SM; Lin HH; Lee TC; Chen PJ; Chu HC; Chang WK; Jeng KS; Lai MM; Chao YC
    Pharmacogenet Genomics; 2007 Apr; 17(4):229-36. PubMed ID: 17496722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-step identification of all length polymorphisms in the UGT1A1 gene promoter.
    Skarke C; Grösch S; Geisslinger G; Lötsch J
    Int J Clin Pharmacol Ther; 2004 Mar; 42(3):133-8. PubMed ID: 15049432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
    Innocenti F; Iyer L; Ratain MJ
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):596-600. PubMed ID: 11259359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
    Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
    J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilirubin UDP-glucuronosyltransferase 1A1 (UGT1A1) gene promoter polymorphisms and HPRT, glycophorin A, and micronuclei mutant frequencies in human blood.
    Grant DJ; Hall IJ; Eastmond DA; Jones IM; Bell DA
    Mutat Res; 2004 May; 560(1):1-10. PubMed ID: 15099818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
    Innocenti F; Ratain MJ
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.
    Liu JY; Qu K; Sferruzza AD; Bender RA
    Anticancer Drugs; 2007 Jul; 18(6):693-6. PubMed ID: 17762398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
    Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
    Innocenti F; Grimsley C; Das S; Ramírez J; Cheng C; Kuttab-Boulos H; Ratain MJ; Di Rienzo A
    Pharmacogenetics; 2002 Dec; 12(9):725-33. PubMed ID: 12464801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
    Liu Y; Ramírez J; House L; Ratain MJ
    Eur J Cancer; 2010 Jul; 46(11):2097-103. PubMed ID: 20580994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.
    Wang H; Bian T; Jin T; Chen Y; Lin A; Chen C
    Pharmacogenomics; 2014 Apr; 15(6):785-98. PubMed ID: 24897286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of new missense mutation with [A(TA)7TAA] dinucleotide repeat in UGT1A1 gene promoter causes Gilbert's syndrome.
    D'Angelo R; Rinaldi C; Donato L; Nicocia G; Sidoti A
    Ann Clin Lab Sci; 2015; 45(2):202-5. PubMed ID: 25887876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.